Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 88,1 M
EBIT 2017 -157 M
Net income 2017 -154 M
Finance 2017 166 M
Yield 2017 -
Sales 2018 144 M
EBIT 2018 -97,8 M
Net income 2018 -104 M
Finance 2018 28,0 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 13,0x
EV / Sales2018 8,87x
Capitalization 1 308 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. operates as a biopharmaceutical company which focuses on the development of breakthrough treatments for human disease.It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications.The company was... 
Sector
Biotechnology & Medical Research
Calendar
09/25 | 10:10pmPresentation
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
09/21 LEXICON PHARMACEUTICALS : European Commission Approves Xermelo for the Treatment..
09/19 LEXICON PHARMACEUTICALS : European Commission Approves Xermelo® (Telotristat eth..
09/15 LEXICON PHARMACEUTICALS INC. : - New England Journal of Medicine Publishes Data ..
09/14 LEXICON PHARMACEUTICALS : Reports Positive Pooled Continuous Glucose Monitoring ..
09/14 LEXICON PHARMACEUTICALS : to Present New Clinical Data at the European Associati..
09/12 LEXICON PHARMACEUTICALS : Reports Positive Pooled Continuous Glucose Monitoring ..
09/11 LEXICON PHARMACEUTICALS : to Present at the Bank of America Merrill Lynch 2017 G..
09/11 LEXICON PHARMACEUTICALS : Announces Four Data Presentations at the European Soci..
09/07 LEXICON PHARMACEUTICALS : to Present New Clinical Data at the European Associati..
09/06 LEXICON PHARMACEUTICALS : to Present New Clinical Data at the European Associati..
More news
Sector news : Bio Therapeutic Drugs
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More
2015 Lexicon Undervalued As It Approaches A Major Event
2015 Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning..
2015 Lexicon Pharmaceuticals EPS in-line, beats on revenue
2015 Lexicon Pharmaceuticals - A Diamond In The Rough?
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,6 $
Spread / Average Target 115%
EPS Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & EVP-Clinical Development
Frank P. Palantoni Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICALS, INC.12.10%1 308
AMGEN28.70%135 544
CELGENE CORPORATION24.61%112 572
GILEAD SCIENCES15.40%108 744
REGENERON PHARMACEUTICALS19.36%46 367
VERTEX PHARMACEUTICALS107.30%38 136